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1 Drug description 
Generic/Brand name:  
Plerixafor (Mozobil ®) 
Developer/Company:  
Genzyme Europe B.V., Netherlands 
Description:  
The active substance in Mozobil is plerixafor. It is used to mobilize hemato-
poietic stem cells from the bone marrow by blocking the activity of the pro-
tein CXCR4/SDF-1α a chemokine receptor. This protein is responsible for 
the homing of the hematopoietic stem cells (HSC) within the bone marrow 
(BM). Details about this process are described elsewhere [1]. As plerixafor 
blocks the activity of CXCR4/SDF-1α, stem cells can be released into the 
peripheral blood and can then be collected by aphaeresis [2-4]. 
The advantages of adding plerixafor to G-CSF compared to G-CSF alone are 
increased mobilization of CD34+ cells from the bone marrow into the pe-
ripheral blood and a decreased number of aphaeresis sessions needed to 
reach the target CD34+ stem cell dose in most patients [4]. CD34+ is a pro-
tein located at the surface of hematopoietic stem and progenitor cells. It is 
used as a marker to assess whether an adequate number of HSC are circulat-
ing in the peripheral blood for HSCT [5]. 
The recommended dose of plerixafor is 0.24 mg/kg body weight/day admin-
istered subcutaneously (sc) 6 -11 hours prior to aphaeresis on the evening of 
the fourth day of pre-treatment with the cytokine granulocyte colony-
stimulating factor (G-CSF). G-CSF is given at a dose of 0.01mg/kg daily in 
the morning. The combination of G-CSF and plerixafor was given in clinical 
trials on 2-4 consecutive days, resulting in a maximum of 8 days of G-CSF 
and 4 days of plerixafor administration [2]. In patients with renal impair-
ment (creatinine clearance ≤50 mL/min) the dose of plerixafor should be 
reduced by one third to 0.16 mg/kg [6-7]. Although the dosage of plerixafor 
is linked to the actual body weight of the patient the maximum daily dose of 
plerixafor should not exceed 40 mg [2]. 
2 Indication 
Mozobil is indicated in combination with G-CSF to enhance mobilization of 
haematopoietic stem cells to the peripheral blood for collection and subse-
quent autologous transplantation in patients with lymphoma and multiple 
myeloma whose cells mobilize poorly [2]. 
Only patients in first or second complete or partial remission are considered 
for high-dose chemotherapy and therefore for autologous hematopoietic 
stem cell transplantation (HSCT) [8-9]. 
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3 Current regulatory status 
In July 2009, the EMA granted market authorisation for Mozobil ® (plerixa-
for, AMD3100) in combination with G-CSF (filgrastim, Ratiograstim ®) for 
the mobilization of HSC in patients suffering from lymphoma or multiple 
myeloma who are eligible for autologous HSCT and whose cells mobilize 
poorly [2]. 
In the US, the FDA approved plerixafor in combination with G-CSF for the 
mobilization of HSC to the peripheral blood for the collection and subse-
quent autologous transplantation for patients with Non-Hodgkin’s Lym-
phoma (NHL) and multiple myeloma (MM) in December 2008 [3]. 
Orphan drug designation for plerixafor was granted by the EMA in 2004 and 
by the FDA in 2003 [10-11]. 
4 Burden of disease 
Plerixafor is intended to be used in patients suffering from haematological 
malignancies such NHL, Hodgkin Lymphoma (HL) and MM who are eligi-
ble for high-dose chemotherapy supported by autologous HSCT and who are 
considered to be poor mobilizers. Stem cells can be harvested with different 
methods such as mobilization of the progenitor cells from the bone marrow 
into the peripheral blood (autologous or allogenic transplantation) or by col-
lecting the stem cells directly from the bone marrow [1, 5]. The use of stem 
cells collected by aphaeresis of peripheral blood is widely predominant in 
the world [12]. 
Approximately 35,000 autologous HSCTs are currently performed world-
wide each year to treat a variety of malignant and non-malignant conditions. 
According to Uy et al. (2008) NHL and MM are the most common indica-
tions for autologous transplantation. Also NHL and MM patients are some-
times considered to be poor mobilizers and are therefore eligible for the 
stem cell mobilization with plerixafor [5]. Plerixafor is intended to be used 
for the mobilization of stem cells in NHL, HL and MM patients either in 
first or second complete or partial remission. Within the European Public 
Assessment Report (EPAR) for plerixafor, a calculated prevalence for mobi-
lizing progenitor cells prior to HSCT was <0.6 per 10,000 EU population 
stated [2]. Applying the estimates of the EMA the number of patients eligi-
ble for the mobilization of hematopoietic stem cells would result in a maxi-
mum of 480 in Austria, if plerixafor would be used upfront to mobilize all 
NHL and MM patients. If only patients mobilizing poorly at day 4 of G-CSF 
with or without chemotherapy would be treated with plerixafor, this number 
would be estimated to be much lower. Furthermore, the role of autologous 
HSCT in myeloma is questioned by the introduction of highly active new 
drugs (Bortezomib, Lenalidomide, etc.) [13] and needs to be re-explored in 
future studies [4]. 
The main indication for plerixafor are poor mobilizers. Out of the patients 
eligible for HSCT an estimated 10-30% are poor mobilizers and therefore 
eligible for HSC mobilization with plerixafor. Poor mobilizers are defined as 
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not being able to collect at least 2 x 106 CD34+ cells/kg with current stan-
dard of care [5-6, 14-15]. Factors predicting poor mobilization of HSC are 
advanced age, amount of previous myelosuppressive chemotherapy and ra-
diation, number of chemotherapy regimen, interval from last chemotherapy, 
refractory disease and hypocellular marrow [1, 5].  
 
The three indications, NHL, HL and MM are briefly described below: 
Non-Hodgkin’s Lymphoma 
NHLs encompass a heterogeneous group of diseases originating from cells of 
the lymphatic system such as B-lymphocytes, T-lymphocytes or natural kil-
ler (NK)-lymphocytes [8, 16]. About 90% of NHL are B-cell lymphomas and 
about 10% of NHL cases are T-cell and NK lymphomas [16]. According to 
Statistik Austria 514 peopled died of NH disease and 1057 new cases were 
diagnosed in 2007 in Austria [17]. Thus, in 2007 the incidence of NHL was 
7.6 per 100,000 (9.5 for men and 6.1 for women) [17].  
Since 2001 the World Health Organization (WHO) classification is the in-
ternationally accepted classification of NHL, which is a refinement of the 
REAL (Revised European-American Classification of Lymphoid neoplasm) 
classification. Further, the stages of NHL follow the Ann-Arbor-Staging sys-
tem (stages I-IV and addition of the letters A or B; A=no common symptom 
observed, B=common symptom observed) where existence, frequency and 
localisation of extra-lymphatic involvement are observed [9]. The Ann-Arbor 
Staging system is primarily used to describe the extension of the diagnosed 
lymphoma and to choose the right therapy option. Further, information on 
prognosis of the disease development can be given [16]. 
According to the international lymphoma classification project the most 
common histological types, comprising about 90% of the NHL cases in the 
United States are diffuse large B-cell (DLBCL, 31%), follicular lymphoma 
(FL, 22%), small lymphocytic lymphoma/chronic lymphocytic leukaemia 
(SLL/CLL, 6%), mantle cell lymphoma (MCL, 6%), peripheral T-cell lym-
phoma (PTCL, 6%), marginal zone B-cell lymphoma (MZL), mucosa-
associated lymphoid tissue (MALT) lymphoma (5%) [8]. 
Morbus Hodgkin/Hodgkin Lymphoma 
According to Statistik Austria the incidence of HL was 1.7 per 100,000 (2 for 
men and 1.4 for women) in Austria in 2007 [18]. The classification and stag-
ing of HL follows like NHL the WHO classification or the Ann-Abor Stag-
ing [16, 19]. The distribution of HL is bimodal with peaks at the age of 20-30 
years and at 70 years [9, 19]. 
HLs are very sensitive to chemo- and radiation therapy. About 50-60% for 
patients suffering from advanced disease and up to 90% for patients with lo-
calized HL can be cured [9]. Relapse is observed in about 25-30% of HL pa-
tients. Choice of therapy for early relapsed patients is high-dose chemother-
apy supported by autologous HSCT four younger patients [9]. Assuming 136 
cases of HL in Austria per year, a relapse rate of 27% and that only patients 
<65 years of age are eligible for HSCT, less than 37 HL patients are eligible 
for autologous HSCT. 
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Multiple Myeloma 
The incidence of MM was about 2.5 per 100,000 (2.8 for men and 2.1 for 
women) in 2007 in Austria. In absolute numbers 180 men and 198 women 
were diagnosed with plasmacytoma in Austria in 2007 [20]. Median age at 
time of diagnosis is 65 years [16]. MM is considered to be very sensitive to 
cytotoxic drugs. However, no curative treatment approach for this disease 
exists yet [13]. At diagnosis smoldering (asymptomatic) and active (symp-
tomatic) disease can be distinguished. Further, the symptomatic disease is 
classified according to stages following the Durie-Salmon staging system or 
the International Staging System. Both staging systems have three different 
levels (stage I-III) and Durie-Salmon uses the letters A (normal renal func-
tion; serum creatinine level <2.0 mg/dL) and B (serum creatinine level ≥2.0 
mg/dL) for sub-classification within the different stages [13]. Besides the 
dissemination of tumour mass the Durie-Salmon staging system gives prog-
nostic information regarding survival of MM patients [21]. The overall sur-
vival had varied between a few months and a couple of years not at last de-
pending on treatment with standard-dose chemotherapy (mean 3 years) and 
high-dose therapy (4-5 years) [21], until the introduction of novel agents 
(thalidomide, bortezomib, lenalidomid) initiating at least a doubling of 
these figures in the last years [13]. 
5 Current treatment 
For haematological malignancies such as NHL, HL and MM high-dose 
chemotherapy supported by autologous HSCT is considered to be standard 
of care in patients under the age of 65 years in first or second complete or 
partial remission [6, 8]. The amount of CD34+ cells in the peripheral blood 
is currently the most widely used indicator for adequate stem cell mobiliza-
tion. A consensus on the minimum amount of CD34+ cells needed for 
autologous HSCT has not been established yet between different research 
groups. The total CD34+ cell count in the peripheral blood should be at 
least 2 x 106 cells/kg. The target cell count of ≥5 x 106 cells/kg is associated 
with faster neutrophil and platelet engraftment and a decreased need for 
supportive measures such as antibiotics and transfusions. Therefore, the 
preferred target cell count for HSCT is ≥5 x 106 CD34+cells/kg [1, 22]. 
However, as it is difficult to collect ≥5 x 106 cells/kg in heavily pre-treated 
patients the collection of at least 2 x 106 cells/kg is necessary for autologous 
HSCT [1-2, 22]. 
Different options exist for mobilizing HSC from the bone marrow into the 
peripheral blood for aphaeresis: 
 Cytokine (G-CSF or granulocyte macrophage colony-stimulating 
factor (GM-CSF)) monotherapy: sc 0.01 mg/kg per day for up to 5 
days followed by leukaphaeresis daily (mean 1-5 days) until the tar-
get number of stem cells has been collected [1, 6]. 
 Cytokines plus chemotherapy (mainly cyclophosphamid [4]): The 
use of this combination requires fewer leukaphaeresis but also in-
creases the risk of complications and shows significantly higher tox-
icities compared to G-CSF alone. These toxicities include increased 
risk for secondary malignancies, impairment of fertility, cardiac 
incidence: ˜2.5 per 
100.000 
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OS: depending on 
treatment and stage of 
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high-dose 
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toxicity, hemorrhagic cystitis and anaphylactic reactions. Further, 
the addition of chemotherapy to G-CSF does not reduce the risk of 
mobilizing and collecting tumour cells1 and does not show a sur-
vival benefit after 12 months in comparison to patients treated with 
G-CSF [1]. 
Currently, no uniform strategy exists for the management of poor mobiliz-
ers, whose initial mobilization attempt failed. Though, several options for 
remobilization exist [1, 5]: 
 Dose escalation of G-CSF, 
 addition of other cytokines (GM-CSF) to G-CSF, 
 mobilization with chemotherapy and cytokines, 
 harvesting cells directly from the bone marrow (BM) and 
 use of novel agents alone or in combination with G-CSF [1]. 
Despite these strategies up to 30% of patients failing the initial mobilization 
still do not reach the minimum amount of CD34+ cells required for trans-
plantation after remobilization [5]. 
6 Evidence 
According to the EPAR of the EMA 22 studies (two phase II studies, two 
phase III studies, eight clinical pharmacology and ten supportive studies) 
and one compassionate use program (CUP) for the use of plerixafor were 
considered in the marketing authorisation application process. Out of these 
22 studies two phase III studies assessing the safety and efficacy of plerixa-
for in the mobilization of progenitor stells for HSCT, four phase II studies 
as well as major findings of the CUP are discussed in this report.  
One of the phase III studies observed the clinical effectiveness of plerixafor 
in patients with MM and the other one in patients with NHL, both com-
pared to placebo [14, 23]. Of the 600 (Intervention 298 vs Control 302) pa-
tients recruited in these phase III trials 544 (I 91.6% vs C 89.7%) were alive 
at the 12 months follow-up. 
One phase II [24] study assessed, besides the efficacy of plerixafor, the pos-
sibility of tumour cell contamination of the aphaeresis product in patients 
with MM who are proven or predicted poor mobilizers. Flomenberg et al. 
                                                             
1 The protein CXCR4, to which plerixafor is binding is not only expressed on the cell 
surface of, but also on the surface of cells of solid tumour malignancies. Therefore 
the potential for tumour cell mobilization is currently clinically investigated 1.
 Pusics, I. and J. DiPersio, The Use od Growth Factors in Hematopoietic 
Stem Cell Transplantation. Current Pharmaceutical Design, 2008. 14: p. 1950-
1961, 5. Uy, G.L., et al., Plerixafor, a CXCR4 antagonist for the 
mobilization of hematopoietic stem cells. Expert Opinion on Biological Therapy, 
2008. 8(11): p. 1797-804, 22. Tricot, G., M. Cottler-Fox, and G. Calandra, 
Safety and efficacy assessment of plerixafor in patients with multiple myeloma 
proven or predicted to be poor mobilizers, including assessment of tumour cell 
mobilization. Bone Marrow Transplantation, 2010. 45: p. 63-68.. 
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(2005) [25] investigated the superiority of plerixafor to G-CSF in MM and 
NHL patients and Cashen et al. (2008) [26] in patients with HL. Stewart et 
al. (2009) [22] conducted a phase II trial to investigate the safety, efficacy, 
pharmacokinetic and pharmacodynamic of plerixafor in NHL and MM pa-
tients. 
6.1 Efficacy and safety - Phase III studies 
Table 6.1-1: Evidence table of Phase III trials 
Reference  DiPersio et al. 2009 [23] 
(multiple myeloma, protocol AMD3100-3102) 
 DiPersio et al. 2009 [14] 
(non-hodgkin’s lymphoma, protocol AMD3100-3101) 
Sponsor Genzyme Corporation  Genzyme Corporation, Cambridge, MA (formerly 
AnorMED Inc.) 
Country Multicenter, 40 sites in 3 countries (United States, 
Canada, Germany) 
 Multicenter, 32 sites 
Design Randomized, double-blind, placebo-controlled  Randomized, double-blind, placebo-controlled 
Participants char-
acteristics 
302 patients (pts) 
I(ntervention) 148 pts, median age 58.2 ±8.4 years 
C(ontrol) 154 pts, median age 58.4 ±8.6 years  
 298 pts 
I(ntervention)  150 pts, median age, years: 56 (range 
29-75;) 
C(ontrol) 148 pts, median age, years: 59 (range 22-75) 
Treatments I(ntervention): G-CSF + plerixafor (AMD3100) 
0.24 mg/kg (actual body weight) sc daily for up to 
4 days or until ≥6 x 106 CD34+ cells/kg were col-
lected. 
 
C(ontrol): G-CSF + placebo sc daily for up to 4 
days or until ≥6 x 106 CD34+ cells/kg were col-
lected. 
 
Aphaeresis began on day 5 and continued daily for 
up to 4 days or until ≥6 x 106 CD34+ cells/kg were 
collected. 
 I(ntervention): G-CSF + plerixafor 0.24 mg/kg (actual
body weight) sc daily for up to 4 days or until ≥5 x 106
CD34+ cells/kg were collected. 
 
C(ontrol): G-CSF +  placebo sc daily in the evening for 
up to 4 days or until ≥5 x 106 CD34+ cells/kg were col-
lected. 
 
Aphaeresis began on the morning of day 5 and con-
tinued daily for up to 4 days or until ≥5 x 106 CD34+ 
cells/kg were collected. 
In-/exclusion crite-
ria 
Inclusion: 
age 18-78, biopsy confirmed multiple myeloma, 
first or second complete or partial remission, ≥4 
weeks since last cycle of chemotherapy, eligible 
for autologous HSCT3, ECOG PS4 0 or 1 
 
Exclusion:  
comorbid condition which rendered pts at high 
risk from treatment complication, st.p. autologous 
or allogeneic transplantation, failed previous he-
matopoetic stem cell collections or attempts 
 Inclusion: 
age 18-78, biopsy confirmed NHL, first or second 
complete or partial remission, ≥4 weeks since last cy-
cle of chemotherapy, eligible for autologous HSCT, 
ECOG PS 0 or 1, WBC7 count higher than 2.5 x 109/L,  
 
Exclusion: 
comorbid condition which rendered pts at high risk 
from treatment complication, failed previous HSC col-
lections or collection attempts 
Follow-up 12 months after transplantation  12 months after transplantation 
Outcomes Primary: proportion of pts collecting ≥6 x 106 
CD34+ cells/kg (actual body weight) in ≤ 2 aphae-
resis days. 
Secondary: proportion of pts collecting ≥6 x 106 
CD34+ cells/kg in ≤ 4 aphaeresis days; proportion 
of pts collecting ≥2 x 106 CD34+ cells/kg in ≤ 4 
aphaeresis days; number of aphaeresis days re-
quired to reach ≥6 x 106 CD34+ cells/kg; propor-
tion of pts maintaining a durable graft at 12 
m(on)ths; number of days to neutrophil and 
platelet engraftment; number of fold-increase in 
the number of PB CD34+ cells on each aphaeresis 
day. 
 Primary: proportion of pts able to mobilize ≥5 x 106 
CD34+ cells/kg (actual body weight) in ≤ 4 aphaeresis 
days. 
Secondary: proportion of pts able to mobilize ≥2 x 106
CD34+ cells/kg in ≤ 4 aphaeresis days; number of 
aphaeresis days required to reach ≥5 x 106 CD34+ 
cells/kg; fold-increase in the number of PB CD34+ 
cells before and after study treatment; number of 
days to neutrophil and platelet engraftment; propor-
tion of pts maintaining a durable graft at 12 mths. 
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Key results  
 
Primary: collection of ≥6 x 106 CD34+ cells/kg in ≤ 
2 aphaeresis days: I 71.6% vs. C 34.4%, p<0.001; 
Secondary: collection of ≥6 x 106 CD34+ cells/kg in 
≤ 4 aphaeresis days: I 75.7% vs C 51.3%, p<0.001; 
collection of ≥2 x 106 CD34+ cells/kg in ≤ 4 aphae-
resis days: I 95.3% vs C 88.3%, p=0.031; 
Median number of aphaeresis days required to 
reach ≥6 x 106 CD34+ cells/kg: I 1 day vs C 4 days; 
number of fold-increase in the number of PB 
CD34+ cells from day 4 to day 5: I 4.8-fold vs C 1.7-
fold, p<0.001. 
pts undergoing transplantation: I 148 (95.9%) vs C 
136 (88.3%) 
successful neutrophil engraftment: I 99.3% vs C 
100%, median time to engraftment was 11 days in 
both groups; 
successful platelet engraftment: 99.3% in each 
group after a median time of 18 days. 
graft failures at 12 mths: none identified in both 
groups 
OS at 12 mths: I 141 (95.3%) vs C 148 (96.1%) 
 Primary: proportion of pts able to mobilize ≥5 x 106 
CD34+ cells/kg : I 59.3 % vs. C 19.6%, p<0.001; 
Secondary: proportion of pts able to mobilize ≥2 x 106
CD34+ cells/kg: I 86.7% vs. C 47.3% p<0.001; 
median number of aphaeresis days required to reach 
≥5 x 106 CD34+ cells/kg: I 3 days vs C not estimable; 
median fold increase in PB CD34+ cell count from day 
4 to 5: I 5.0 (range 0.6 - 49.8) vs C 1.4 (range 0.0 – 
13.0); 
all pts who underwent transplantation (I 90% vs C 
55.4%) had successful neutrophil engraftment (me-
dian time to engraftment 10 days) and 98% had suc-
cessful platelet engraftment (median time to en-
graftment 20 days). 
graft failures at 12 mths: I 2 vs C 0. 
OS at 12 mths: I 132 (88%) vs C 129 (87.2%). 
OS at 12 mths for pts who had undergone HSCT (I 135, 
C 82): I 119 (88.1%) vs C 71 (86.6%) 
Adverse effects 
(AEs) 
AEs related to study treatment (periode 1) were 
more frequent in the intervention group than in 
the control group, 64.6% vs 44.4%, respectively. 
Diarrhea: I 18.4% vs C 5.3% 
Nausea: I 16.3% vs C 7.3% 
Vomiting: I 5.4% vs C 2.7% 
Fatigue: I 8.2% vs C 3.3% 
Injection site erythema: I 20.4% vs C 3.3% 
Bone pain: I 9.5% vs C 7.9% 
Headache: I 5.4% vs C 8.6% 
Parestesia: I 7.5% vs C 7.3% 
 
AEs leading to discontinuation of study treat-
ment: I 1 vs C 2; all 3 remained in the study. 
AES leading to study withdrawal: I 4 vs C none re-
ported 
 AEs related to study treatment (period 1) were more 
frequent in the intervention group 65.3% vs 41.4% in 
control group. 
Diarrhea: I 38% vs C 6.2% 
Nausea: I 17.2% vs C 5.5% 
Abdominal pain: I 6% vs C 1.4% 
Injection site erythema: I 29.3% vs C 6.2% 
Bone pain: I 10.7% vs C 6.9% 
Headache: I 11.3% vs C 6.2 
 
AEs leading to discontinuation of study treatment: I 3 
vs C 3  
serious AE by study period5 (regardless of relatedness 
to study treatment): 
Period 1: I 5.3% vs C 6.9% 
Period 2: I 18.5% vs C 20.7% 
Period 3: I 20.0% vs C 17.1% 
Withdrawal from study (not study drug related): I 2 
vs C 5 
Commentary   No differences in early post-transplantation outcomes
between the two study groups including engraftment,
graft durability and patient survival. Long term fol-
low-up of these pts will allow for the assessment of
disease-free survival as the potential of tumour cell
mobilization of plerixafor is not yet  sufficiently in-
vestigated. 
2 sc – subcutaneous 
3 HSCT – hematopoietic stem-cell transplantation 
4 ECOG PS – Eastern Cooperative Oncology Group Performance Status 
5 Study periods: this study consisted of 3 periods. Period 1, from random assignment 
to the day before high-dose chemotherapy; period 2, from first day of chemo-
therapy to the first day of platelet and neutrophil engraftment (whichever was 
later) after transplantation; period 3, from the first day after engraftment 
through 12 months after transplantation. In periods 2 and 3 adverse events 
were evaluated only in patients who underwent transplantation. 
7 WBC – white blood cells 
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For patients not collecting ≥2x106 CD34+ cells/kg in ≤4 aphaeresis days or 
<0.8x106 CD34+ cells/kg in 2 days for single or tandem transplantation, 
both studies provided an open-label rescue procedure consisting of a mini-
mum 7-day rest period without treatment followed by a treatment strategy 
similar to the intervention group. Out of 62 (I 10 pts vs C 52 pts) NHL pa-
tients who received the rescue procedure, 37 (I 4 pts vs C 33 pts) achieved 
≥2x106 CD34+ cells/kg in ≤4 aphaeresis days with the rescue procedure 
and 52 patients underwent transplantation [14]. In the other trial, the 7 MM 
patients entering the rescue procedure had been treated with placebo + G-
CSF and mobilized enough CD34+ cells to undergo transplantation. All 7 
MM patients had a successful neutrophil and platelet engraftment and were 
alive at 12 months’ follow-up. 
In order to conduct a reliable safety analysis the safety reporting of the two 
phase III studies was organized in study periods. Period one was from ran-
dom assignment to the day before high-dose chemotherapy. In this period 
the study drug was administered. Periods 2-3 in NHL patients and periods 
2-5 in MM patients involved the transplantation procedure and post-
transplant time periods until 12 months follow-up [27]. 
AEs occurring in period 1 of each study are presented above in Table 6.1-1. 
The majority of AEs occurred in period 2-5 and were expected and common 
after high-dose therapy and HSCT. During period 1 three NHL patients ex-
perienced severe adverse events (SAEs; I hypotension and dizziness, throm-
bocytopenia vs C nonischemia chest pain). Within the MM study the most 
common AEs in period 1 considered to be study drug related were gastroin-
testinal disorders and injection site reactions. 
At the 12 months follow-up 273 (91.56% of 298) patients treated with 
plerixafor + G-CSF and 277 (91.65% of 302) patients treated with G-CSF + 
placebo were alive. One trial did not report on the patients lost to follow-up 
[14], whereas the other phase III trial reported 13 deaths within the 12 
months’ follow-up period. The most common cause of death was due to dis-
ease progression (I 3 of 7 deaths vs C 5 of 6 deaths) [23]. 
6.2 Efficacy and safety - further studies 
Additional to the phase III studies, four phase II trials and one Compassion-
ate Use Protocol (CUP) including poor mobilizers were identified [22, 25-26, 
28]. 
Flomenberg et al. 2005 [25] conducted a phase II trial (Protocol AMD3100-
2101) to assess whether plerixafor in combination with G-CSF is able to mo-
bilize more progenitor cells per unit of blood volume than G-CSF alone. 25 
patients with MM or NHL (10 MM, 15 NHL), either in first or second com-
plete or partial remission, were randomly assigned to receive either the 
combination of plerixafor and G-CSF or G-CSF as an initial mobilizing 
regimen. Plerixafor was given at a dose of 160 μg/kg for the first 8 patients 
and at an increased dose of 240 μg/kg for the following patients in the eve-
ning of day 4 and was also continued daily until day 8. After a washout pe-
riod remobilization with the other treatment option followed. 24 patients 
underwent transplantation and one patient was excluded from transplanta-
tion for reasons not related to the study. After G-CSF administration alone 8 
patients reached the target of ≥5x106 CD34+ cells/kg, whereas 20 patients 
rescue procedure for pts 
not achieving primary 
or secondary study 
endpoints 
I 10 vs C 52 
reporting of AEs 
organized in study 
periods 
period 1: plerixafor 
administration 
SAEs period 1: 
hypotension, dizziness, 
thrombocytopenia, 
nonischemia, chest pain 
12 months’ OS: I 91.56% 
vs C 91.65% 
4 phase II trials and one 
CUP 
superiority of plerixafor 
+ G-CSF compared to G-
CSF 
 
dose adaption 
 
pts changed treatment 
arms 
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receiving the combination plerixafor + G-CSF reached this target. Gener-
ally, 12 patients required fewer aphaeresis sessions to reach ≥5x106 CD34+ 
cells/kg when treated with AMD3100 (plerixafor) + G-CSF in comparison 
to G-CSF alone. One patient died due to sepsis and hypotension, five other 
patients experienced severe AEs (abdominal pain, jugular vein thrombosis, 
hematuria, neutropenic colitis, catheter infection and gastroenteritis) none 
of these was felt to be study drug related. The most frequent study drug re-
lated AEs were mild and included diarrhoea, injection site redness and nau-
sea and bone pain. 
Cashen et al. 2008 [26] conducted a phase II study to determine if the addi-
tion of plerixafor to mobilization regimens is also effective and safe in pa-
tients with HL. A mobilisation regimen consisting of G-CSF was given to 
each of the 22 relapsed and refractory HL patients included in the study. 
The results were compared with a historical control group composed of 98 
patients with HL who underwent G-CSF mobilization and peripheral blood 
stem cell (PBSC) collection. The main outcome of collecting ≥5x106 CD34+ 
cells/kg was achieved by 15 patients (68%) in the combination arm and by 
15 patients (15%, p>0.001) in the G-CSF alone arm. The target of ≥2x106 
CD34+ cells/kg collection was reached by 21 (95%) patients treated with G-
CSF + plerixafor and by 76 (78%, p=0.071) patients treated with G-CSF 
alone. The median number of CD34+ cells collected on days 1-2 was 
6.2x106/kg and 3.0x106/kg (p<0.001) in the intervention group and in the 
historic control group, respectively. The mean number of aphaeresis session 
was 2.5 in the intervention group and 2.9 in the control group. AEs possibly 
related to plerixafor were injection site erythema or irritation (n=13), diar-
rhea (n=3), nausea (n=2), vomiting (n=1) and abdominal pain or discom-
fort (n=2). 
Stewart et al. (2009) [22] investigated the safety, efficacy, pharmacokinetic 
(PK) and pharmacodynamic (PD) in 22 (8 with NHL, 14 with MM) patients 
in a phase II, open-label single-arm study. Patients received the common 
mobilization regimen consisting of 10 μg/kg G-CSF every day in the morn-
ing and 240 μg/kg plerixafor in the evening of day 4 of G-CSF for up to 5 
days or until ≥5x106 CD34+ cells/kg were collected. All 22 patients reached 
the primary outcome of ≥2-fold increase of CD34+ cells after plerixafor 
administration (from 16.6 to 52.1 cells/μL in NHL patients and from 30.0 to 
86.9 cells/μL in MM patients; median increase of 2.9-fold (NHL 2.7 vs MM 
3.1)). All patients underwent HSCT. Successful polymorphonuclear leuko-
cyte engraftment was shown after a median of 11 days and the mean time for 
platelet engraftment was 18 days. All patients experienced at least one AE. 
AEs considered being study drug related are injection site erythema (36%), 
injection site pain (18%), upper abdominal pain (9%), diarrhea (9%) and 
headache (9%). All of these AEs were mild or moderate. Serious AEs oc-
curred in 8 patients but none was considered to be study drug related. 
Tricot et al. [24] conducted a phase II trial to investigate the safety and effi-
cacy of plerixafor for stem cell mobilization and tumour contamination of 
the aphaeresis product in 20 MM patients who were either proven (n=10) or 
predicted (n=10) poor mobilizers. Both groups had mobilized poorly with 
either G-CSF alone or G-CSF in combination with chemotherapy. The pe-
ripheral blood CD34+ cell count was measured pre- and post-plerixafor and 
showed a significant increase. 17 patients underwent transplantation (1 col-
lected insufficient CD34+ cells for transplantation and two patients decided 
not to proceed with transplantation for the moment). Eight patients were 
transplanted with pooled cells from other collections. At the 12 months fol-
mobilization of HSC in 
HL pts 
 
historical control group 
assessment of PK and 
PD of plerixafor in NHL 
and MM pts 
assessment of tumour 
contamination in 
aphaeresis product of 
poor mobilizers 
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low-up 12 of the 17 patients who underwent transplantation showed durable 
graft, three died (2 due to disease progression and 1 because of cerebral in-
farction) and 2 patients were lost to follow-up. Adverse events occurred in all 
patients – 1 mild, 7 moderate and 12 experienced severe adverse events. 
Drug related AEs were erythema (17 pts), injection site reaction and diar-
rhea (each: 3 pts), fatigue, injection site pruritus, injection site swelling, hot 
flushes (each 2 pts). None of the 25 serious AEs occurring in 8 patients were 
considered to be study drug related. Tumour cell contamination of the 
aphaeresis product was assessed by using flow cytometry (sensitivity 1/100 
cells to quantify tumour cells) in peripheral blood samples taken before the 
first dose of plerixafor and before the subsequent aphaeresis. For final 
analysis 9 paired samples (pre- and post first dose of plerixafor) were used. 
None, except one pre-plerixafor sample showed >1% of light-chain-
restricted cells and no plasma cells with aneuploid DNA could be observed 
in any of the samples. 
The Compassionate Use Protocol (CUP) [28] was established because 
plerixafor trials have generally excluded patients who could not mobilize or 
collect sufficient cells for HSCT. The SPU2 and CUP were initiated to allow 
requests for plerixafor treatment to be addressed in an urgent manner, such 
as when a patient required remobilization within 1-2 weeks. The data avail-
able from the CUP may be limited due to amount and quality of data sent by 
site. Further no comparison to a control group was made. Patients enrolled 
had previously received a conventional mobilization regimen, which re-
sulted in mobilization of insufficient CD34+ cells for transplant. The entry 
to the CUP was limited to patients who had previously failed to proceed to 
aphaeresis due to low peripheral blood (PB) CD34+ cell counts. Calandra et 
al. (2008) reported results of 115 patients representing over 80% of the NHL, 
MM and Morbus Hodgkin patients enrolled in the CUP. More than 66% of 
patients included in the data audit reached the progenitor cell count ≥2x106 
CD34+ cells/kg. More than 75% of patients were able to proceed to trans-
plantation. No follow-up data were reported. Of the plerixafor related AEs 
two (1.6%) were severe, 17 (13.6%) were moderate and 106 (84.8%) were 
mild. Most common AEs related to AMD3100 were gastrointestinal (diar-
rhoea 17.4%, nausea 9.6%), injection site (erythema 15.7%) and nervous sys-
tem (paresthesia and oral paresthesia 6.9%). The two severe AEs that were 
study drug related were headache and nightmares. Out of the 115 pts in-
cluded in this data analysis 15 died – deaths were not related to AMD3100. 
7 Estimated costs 
Cost estimates for 20 mg/ml Mozobil ® (plerixafor) are € 5,537.- [29]. Gen-
erally one vial consists of 24 mg plerixafor in 1.2ml solution [30] resulting in 
€ 6,644 for one vial. 
                                                             
2 SPU Protocol allow patients who do not qualify for ongoing trials to have access to 
unlicensed drugs 7. Calandra, G., et al., AMD3100 plus G-CSF can 
successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's 
disease and multiple myeloma patients previously failing mobilization with 
chemotherapy and/or cytokine treatment: Compassionate use data. Bone Marrow 
Transplantation, 2008. 41(4): p. 331-338. 
CUP for pts excluded 
from clinical trials 
9 paired samples – no 
tumour cell 
contamination observed 
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Assuming an average weight of 75 kg for NHL, HL or MM patients the daily 
dose of plerixafor would be 18 mg. Therefore one dose of plerixafor would 
cost € 6,644. As plerixafor can be given up to four consecutive days, treat-
ment costs can range between € 6,644 and € 26,576. Plerixafor is approved to 
be given in addition to G-CSF, therefore the costs for G-CSF have to be 
added. One injection of filgrastim consists of 0.48 mg in 0.8 ml solution and 
costs € 99.94 [31]. 
Additional, costs for high-dose chemotherapy and HSCT have to be consid-
ered. Plerixafor is intended to reduce hospitalization costs due to fewer 
aphaeresis sessions needed to harvest a sufficient amount of CD34+ cells in 
fewer aphaeresis sessions. Whether plerixafor reduces hospitalization rates 
or not, has not been addressed within the trials included in this report. 
8 Ongoing research 
According to ClinicalTrials.gov, a service of the U.S. National Institutes of 
Health, one phase III trial and several phase II trials are ongoing. 
Phase III trial NCT00838357 – this trial is a multicenter, open label single-
arm study evaluating the efficacy and safety of plerixafor in lymphoma 
(NHL, HD) and MM patients who are eligible for autologous HSCT. The 
study started in September 2008 and is estimated to be completed in Sep-
tember 2010. 100 patients are planned to be enrolled. 
Phase II trials listed on the website www.clinicaltrials.gov are investigating 
different study aims such as 
 identification of the ideal dose of plerixafor and other mobilization 
agents (G-CSF, chemotherapy) to increase the number of patients 
successfully collecting CD34+ cells, 
 safety analysis whether plerixafor in combination with bortezomib 
may be able to stop myeloma cells attaching the bone marrow, 
 safety of combining plerixafor with other chemotherapy agents for 
allogeneic stem cell transplantation in myeloid leukaemia patients, 
both when plerixafor is given subcutaneously or intravenous and 
 to assess the ability of plerixafor to release chronic lymphoceutic 
leukaemia or small lymphocytic lymphoma cells into the peripheral 
blood to enhance the cytotoxic effect of chemotherapy (e.g., rituxi-
mab). 
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9 Commentary 
Up to date two phase III trials assessing the safety and efficacy of plerixafor 
in addition to G-CSF, the current standard agent for mobilization of hema-
tologic stem cells, have been conducted. Both trials were multicenter RCTs 
sponsored by Genzyme Corporation and had similar in- and exclusion crite-
ria and treatment regimens. Both defined the collection of CD34+ cells as 
primary and secondary outcomes (see Table 6.1-1) and showed that the 
CD34+ cell count increased when plerixafor was given additionally to G-
CSF compared to placebo plus G-CSF, in MM patients 95.3% vs 88.3% 
(p=0.031) and in NHL patients 86.7% vs 47.3%, respectively. Also the per-
centage of patients undergoing transplantation was higher in the interven-
tion group (MM 95.9%, NHL 90%) compared to the control group (MM 
88.3%, NHL 55.4%).  
The safety profile of the trials showed an increase in adverse events in the 
intervention group (64.6% - 65.3%) compared to the control group (41.4% - 
44.4%). In the MM study three patients discontinued study treatment due to 
AEs (I 1 patients vs C 2 patients) and four other patients withdrew from the 
study due to AEs [23].  
The most commonly used indicator and predictor for neutrophil and platelet 
engraftment after transplantation is the CD34+ cell count in the peripheral 
blood [1, 26]. This indicator was used in the included phase II and III trials 
to assess the efficacy of plerixafor for mobilizing progenitor cells in NHL, 
HL and MM patients. Besides the mobilisation of a sufficient number of 
CD34+ cells for HSCT, it is expected that plerixafor can improve patients’ 
quality of life, reduces hospitalization costs, allow for more efficient use of 
resources by eliminating the need for additional aphaeresis sessions (e.g., 
personal, blood bank resources) and improves transplant outcomes of infu-
sion of a higher stem cell dose [4, 25-26]. Negative aspects of the addition of 
plerixafor to G-CSF may be the additional costs of plerixafor, increased risk 
of side effects (I 64.6%-65.3% vs C 41.4%-44.4%) and the inconvenience of 
giving an injection the evening prior to aphaeresis [26]. 
According to the summary for the public of plerixafor by EMA patients in-
cluded in the two major phase III studies [14, 23] were adequate or good 
mobilizers [2], though the target population intended to be treated with G-
CSF in combination with plerixafor are poor mobilizers [2, 14]. 
Event though the trials included have shown superiority regarding the re-
duction of aphaeresis days required to collect the pre-defined number of 
CD34+ cells (MM: I 1 day vs C 4 days; NHL: I 3 days vs C not estimable), 
no relevant difference in the 12 months overall survival has been shown, as 
could be expected in trials of this size. Regarding the potential of tumour 
cell mobilization (see below) FDA and EMA considered that a long-term fol-
low-up regarding patient relevant outcomes (progression free survival (PFS), 
OS, relapse rates) is necessary. Thus, Genzyme Corporation committed to 
extending the long-term follow up for the two controlled Phase III studies to 
5 years, including evaluation of relapse, PFS, and overall survival [2, 28]. 
Further, the assessment of quality of life in patients treated with plerixafor 
compared to those not treated with plerixafor is still lacking. Moreover, be-
cause data regarding hospitalization, blood bank and other resources are still 
missing, a possible reduction in resources needed due to harvesting higher 
2 phase III RCTs 
evaluating safety and 
efficacy of plerixafor 
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number of CD34+ cells in fewer aphaeresis sessions can not be demon-
strated. 
The Scottish Medicines Consortium criticised that, at the moment, no com-
parative trials of plerixafor + G-CSF against other regimens such as chemo-
therapy + G-CSF (standard of care in HSCT eligible NHL patients in 
Scottland) do exist [32]. 
Another important concern that needs to be further addressed in clinical tri-
als is the potential ability of plerixafor to mobilize tumour cells. It is re-
ported that plerixafor mobilizes leukaemia cells [24]. Therefore, Mozobil 
cannot be used for mobilization of HSC for transplantation in leukaemia pa-
tients [23]. Tricot et al. address this concern in their phase II trial. They did 
not observe plasma cells with aneuploid DNA content within their 9 paired 
samples and further concluded that their sample size was too small to ex-
clude the potential of tumour cell mobilization by plerixafor in MM patients 
[24]. Also, EMA concluded that this issue has not yet been sufficiently ad-
dressed to either confirm or exclude the potential of tumour cell mobiliza-
tion. If plerixafor in combination with G-CSF mobilizes more tumour cells 
than G-CSF alone, the relapse rate within the intervention arm is expected 
to be higher than in the control arm. For this reason the long-term follow-up 
has been extended to 5 years evaluating relapse, progression-free survival 
and overall survival [2, 27]. 
Although plerixafor added to G-CSF leads to an increase in CD34+ cells in 
the peripheral blood and a reduction in number of aphaeresis days required 
to collect a certain target count of CD34+ cells, there are still questions 
needed to be answered like the potential for tumour cell mobilization, qual-
ity of life in patients, potential for reduction of costs and when to decide to 
give plerixafor for stem cell mobilization to ameliorate the benefit for the 
patient. These concerns are funded especially concerning the upfront use of 
plerixafor in the stem cell collection procedure, while the “rescue” use in 
true poor mobilizers (as defined by low peripheral CD34 counts on day 4 of 
standard G-CSF with or without chemotherapy mobilization protocol) 
seems much less disputable because such patients do not possess a sensible 
treatment alternative. 
no head-to-head trials 
exist 
potential for tumour cell 
mobilization cannot be 
yet excluded 
role of plerixafor in the 
clinical practice needs to 
be  defined 
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